Ultragenyx Pharmaceutical (RARE) announced after the close Wednesday that it Phase 2 study of UX007 in glucose transporter type-1 deficiency syndrome patients with seizures did not meet the primary endpoint.
from RTT - Before the Bell http://ift.tt/2ocRSg0
via IFTTT
No comments:
Post a Comment